fluorobenzenes has been researched along with Hypertension in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (37.78) | 29.6817 |
| 2010's | 28 (62.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Kang, HC; Kim, CM; Kim, YS; Lee, JA; Lee, SY; Oh, HJ; Park, KC; Sin, DH; Sunwoo, S; Yang, YJ; Yu, BY | 1 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR | 1 |
| DiNicolantonio, JJ; Elisaf, MS; Liberopoulos, EN; Rizos, CV; Tellis, K; Tselepis, AD | 1 |
| Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y | 1 |
| Diao, Y; Liu, Z; Lu, F; Qi, Z; Song, H; Wei, F; Ye, L; Zhang, H; Zhao, Y | 1 |
| Bae, JH; Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, S; Lim, DS; Shin, DH; Won, H | 1 |
| Hwang, E; Jang, JY; Kang, DH; Kim, DH; Song, JM; Sun, BJ | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Liu, Y; Ren, L; Wang, P; Wang, Z; Ye, H; Zhao, N | 1 |
| Galeeva, ZM; Galiavich, AS | 1 |
| Blankenberg, S; Everett, BM; Glynn, RJ; Ridker, PM; Zeller, T | 1 |
| Erdmann, E; Hoppe, UC | 1 |
| Fiebeler, A; Haller, H; Luft, FC; Menne, J; Mervaala, EM; Muller, DN; Park, JK | 1 |
| Gibbons, RJ | 1 |
| Akin, KO; Ata, N; Cil, H; Dal, K; Ertugrul, DT; Hokkaomeroglu, MS; Kucukazman, M; Tutal, E; Yalcin, AA; Yavuz, B; Yavuz, BB | 1 |
| Chang, HJ; Chang, SA; Kim, DH; Kim, HK; Kim, YJ; Lee, HW; Oh, BH; Park, YB; Sohn, DW | 1 |
| Brown, L; Chan, V; Hoey, A; Loch, D | 1 |
| Crijns, HJ; De Leeuw, PW; de Vos, C; Folkeringa, RJ; Habets, J; Pinto, YM; Prins, MH; Tieleman, RG; Van Dieijen-Visser, M | 1 |
| Bremner, JD; Kelley, ME; Vaccarino, V | 1 |
| Chae, IH; Chang, HJ; Cho, YS; Choi, DJ; Kim, CH; Kim, HS; Kim, KI; Oh, BH; Park, YB; Suh, JW; Youn, TJ | 1 |
| Ballerio, R; Banfi, C; Blanc-Guillemaud, V; Brioschi, M; Castiglioni, L; Gelosa, P; Gianella, A; Guerrini, U; Lerond, L; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E | 1 |
| Lin, ZP; Shu, PC; Wu, SQ; Zhang, RK; Zhang, ZW | 1 |
| Elisaf, MS; Florentin, M; Kostapanos, MS; Kostara, CE; Liberopoulos, EN; Milionis, HJ; Rizos, CV | 1 |
| da Silva Torres, T; de Carvalho, JJ; Mandarim-de-Lacerda, CA; Neto-Ferreira, R; Novaes Rocha, V | 1 |
| Edin, ML; Li, X; Wang, DW; Wu, B; Yang, G; Zeldin, DC; Zhao, G | 1 |
| Devaraj, S; Jialal, I; Siegel, D | 1 |
| de Barros, EP; de Carvalho, JJ; dos Santos Pereira, MJ; Garcia-Pinto, AB; Machado, PY | 1 |
| Crook, MA; Jewkes, C; Jones, A; Meek, C; Twomey, PJ; Viljoen, A; Wierzbicki, AS | 1 |
| Du, QJ; Ge, JB; Gong, H; Hu, K; Li, H; Qiu, ZH; Sun, AJ; Wu, CN; Zhang, WB; Zhao, G; Zou, YZ | 1 |
| Rehman, HU | 1 |
| Bao, Z; Du, Q; Fan, F; Ge, J; Hu, X; Li, H; Li, Z; Qiu, Z; Sun, A; Wu, C; Ye, Y; Zhang, W; Zhao, G | 1 |
| Barkas, F; Elisaf, MS; Liamis, G; Liberopoulos, EN; Moutzouri, E; Rizos, CV | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Ahn, J; Frohlich, ED; Slama, M; Susic, D; Varagic, J | 1 |
| Blenkinsopp, J | 1 |
| Cremonesi, B; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Paoletti, R; Sironi, L; Tremoli, E | 1 |
| Brown, L; Hoey, A; Levick, S; Loch, D | 1 |
| Chazova, IE; Kaminnaia, VI; Kukharchuk, VV; Ratova, LG | 1 |
| Balligand, JL; De Keyzer, D; Desjardins, F; Herregods, MC; Holvoet, P; Mertens, A; Pelat, M; Sekkali, B; Smith, G; Verreth, W | 1 |
| García-Moll, X | 1 |
| Alvarez-Aguilar, C; Gómez-García, A; Martínez Torres, G; Ortega-Pierres, LE; Rodríguez-Ayala, E | 1 |
| Watts, SW | 1 |
1 review(s) available for fluorobenzenes and Hypertension
| Article | Year |
|---|---|
[Cardiology 2008].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aortic Valve Stenosis; Cardiac Catheterization; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Fluorobenzenes; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
14 trial(s) available for fluorobenzenes and Hypertension
| Article | Year |
|---|---|
Achieving recommended low density lipoprotein cholesterol goals and the factors associated with target achievement of hypercholesterolemia patients with rosuvastatin in primary care.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Republic of Korea; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Smoking; Sulfonamides; Surveys and Questionnaires | 2013 |
Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Angiotensin II Type 1 Receptor Blockers; Aryldialkylphosphatase; Benzimidazoles; Benzoates; Biomarkers; Biphenyl Compounds; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Irbesartan; Lipoproteins, HDL; Male; Middle Aged; PPAR gamma; Prediabetic State; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Telmisartan; Tetrazoles; Treatment Outcome | 2015 |
Anti-sympathetic action enhances statin's pleiotropic effects: the combined effect of rosuvastatin and atenolol on endothelial function.
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Antihypertensive Agents; Atenolol; Biomarkers; Brachial Artery; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Endothelium, Vascular; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Japan; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2014 |
Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis.
Topics: Adult; Aged; Benzimidazoles; Benzoates; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Humans; Hypertension; Male; Middle Aged; Nuclear Receptor Subfamily 1, Group F, Member 3; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; T-Lymphocytes, Regulatory; Telmisartan; Th17 Cells | 2014 |
Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).
Topics: Anticoagulants; Combined Modality Therapy; Double-Blind Method; Drug-Eluting Stents; Electrocardiography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Placebos; Prospective Studies; Pyrimidines; Republic of Korea; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome | 2014 |
Effect of rosuvastatin on coronary flow reserve in patients with systemic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Blood Pressure; Coronary Artery Disease; Coronary Circulation; Dose-Response Relationship, Drug; Echocardiography, Doppler; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Essential Hypertension; Female; Fluorobenzenes; Humans; Hypertension; Hypolipidemic Agents; Lipid Metabolism; Lisinopril; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy.
Topics: Aged; Angina, Unstable; Biomarkers; Cholesterol, HDL; Comorbidity; Coronary Disease; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Primary Prevention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Troponin T | 2015 |
Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins?
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Cohort Studies; Diabetes Mellitus; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vitamin D | 2009 |
No effect of rosuvastatin on left ventricular hypertrophy in patients with hypertension: a prospective randomised open-label study with blinded endpoint assessment.
Topics: Aged; Cholesterol, LDL; Endpoint Determination; Female; Fluorobenzenes; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2010 |
[Effects of rosuvastatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hypertensive patients with mild LDL-C elevation].
Topics: Aged; Arteriosclerosis; C-Reactive Protein; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ventricular Function, Left | 2010 |
Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; C-Reactive Protein; Drug Therapy, Combination; Fasting; Female; Fluorobenzenes; Greece; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Imidazoles; Insulin; Irbesartan; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Telmisartan; Tetrazoles | 2010 |
Effects of manidipine plus rosuvastatin versus olmesartan plus rosuvastatin on markers of insulin resistance in patients with impaired fasting glucose, hypertension, and mixed dyslipidemia.
Topics: Aged; Blood Glucose; Dihydropyridines; Drug Therapy, Combination; Dyslipidemias; Endpoint Determination; Fasting; Female; Fluorobenzenes; Humans; Hypertension; Imidazoles; Insulin Resistance; Male; Middle Aged; Nitrobenzenes; Piperazines; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Single-Blind Method; Sulfonamides; Tetrazoles; Treatment Outcome | 2013 |
[Treatment for dyslipidemias in patients with arterial hypertension].
Topics: Antihypertensive Agents; Cholesterol; Combined Modality Therapy; Drug Therapy, Combination; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Russia; Sulfonamides; Treatment Outcome | 2007 |
30 other study(ies) available for fluorobenzenes and Hypertension
| Article | Year |
|---|---|
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2014 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
[Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients].
Topics: Ankle Brachial Index; Ankle Joint; Atherosclerosis; Blood Flow Velocity; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Pulsatile Flow; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness | 2014 |
Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion.
Topics: Albuminuria; Angiotensin II; Animals; Blood Pressure; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Fibronectins; Fluorescent Antibody Technique, Indirect; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunohistochemistry; Inflammation; Intercellular Adhesion Molecule-1; Kidney; Kidney Cortex; Kidney Medulla; Male; Monocytes; Necrosis; Neutrophil Infiltration; Nitric Oxide Synthase Type II; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Smoking; Sulfonamides | 2009 |
Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy.
Topics: Animals; Blood Pressure; Collagen; Disease Progression; Fibrosis; Fluorobenzenes; Heart; Heart Failure; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Myocardium; Organ Size; Pyrimidines; Random Allocation; Rats; Rats, Inbred Dahl; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin attenuates heart failure and cardiac remodelling in the ageing spontaneously hypertensive rat.
Topics: Aging; Animals; Blood Pressure; Diastole; Disease Models, Animal; Echocardiography; Fluorobenzenes; Heart; Heart Failure; Hypertension; Lipoproteins, LDL; Male; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Systole; Ventricular Remodeling | 2009 |
JUPITER: a few words of caution.
Topics: Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Caveolin 1; Down-Regulation; Drug Administration Schedule; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2010 |
Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin.
Topics: Animals; Aspirin; Biomarkers; Blood Pressure; Brain; Endothelium, Vascular; Fluorobenzenes; Hypertension; Magnetic Resonance Imaging; Male; Naphthalenes; Propionates; Protective Agents; Pyrimidines; Rats; Rats, Inbred SHR; Receptors, Prostaglandin; Receptors, Thromboxane; Rosuvastatin Calcium; Stroke; Sulfonamides; Survival Analysis; Systemic Inflammatory Response Syndrome | 2010 |
Beneficial effects of rosuvastatin on aortic adverse remodeling in nitric oxide-deficient rats.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Disease Models, Animal; Endothelial Cells; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunohistochemistry; Lipids; Microscopy, Electron, Transmission; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Tunica Intima | 2011 |
Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein.
Topics: Animals; Aorta; Blood Pressure; C-Reactive Protein; Down-Regulation; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Superoxide Dismutase; Superoxide Dismutase-1 | 2011 |
CRP induces hypertension in animal models: homo sapiens says no.
Topics: Animals; Blood Pressure; C-Reactive Protein; Endothelium, Vascular; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs).
Topics: Animals; Blood Chemical Analysis; Blood Pressure; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Glomerulus; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosuvastatin Calcium; Sulfonamides | 2011 |
Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Comorbidity; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Smoking; Sulfonamides; Treatment Outcome; Triglycerides; United Kingdom | 2012 |
The therapeutic effect of rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end-stage hypertension in rats.
Topics: Animals; Apoptosis; bcl-Associated Death Protein; Caspase 3; Fibrosis; Fluorobenzenes; Forkhead Transcription Factors; Hypertension; Hypertrophy; Male; Microtubule-Associated Proteins; Myocytes, Cardiac; Nerve Tissue Proteins; Protein Kinase C; Protein Kinase C beta; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, Angiotensin; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Survivin; Ventricular Remodeling | 2012 |
The work-up for mixed hyperlipidemia: a case study.
Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Male; Metformin; Physical Examination; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2012 |
Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.
Topics: Aging; Animals; Blood Pressure; Calcium-Binding Proteins; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Down-Regulation; Electron Transport Complex IV; Fluorobenzenes; Heart Failure; Hypertension; Male; Mitochondria; Myofibrils; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Protein Kinase C beta; Protein Kinase C-alpha; Proteins; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Rosuvastatin Calcium; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Signal Transduction; Sodium-Calcium Exchanger; Stroke Volume; Sulfonamides; Up-Regulation; Ventricular Function, Left | 2012 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models.
Topics: Animals; Fluorobenzenes; Hypertension; Male; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosuvastatin Calcium; Sulfonamides | 2003 |
The stain wars.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; United States | 2003 |
Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects.
Topics: Acute-Phase Proteins; Animals; Cerebral Arteries; Chemokine CCL2; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; P-Selectin; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sodium Chloride, Dietary; Stroke; Sulfonamides; Transcription, Genetic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vasculitis | 2005 |
Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats.
Topics: Animals; Aorta; Blood Pressure; Desoxycorticosterone; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy; Male; Myocardium; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sodium Chloride, Dietary; Sulfonamides; Ventricular Remodeling | 2006 |
Will drugs someday reverse CAD? Three recent advances bring the possibility closer to reality.
Topics: Apolipoprotein A-I; Coronary Artery Disease; Fluorobenzenes; Humans; Hypertension; Hypolipidemic Agents; Pyrimidines; Remission Induction; Rosuvastatin Calcium; Sulfonamides | 2007 |
Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
Topics: Animals; Blood Pressure; Dyslipidemias; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Mice; Mice, Obese; PPAR gamma; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Inflammation, atherosclerosis, classic cardiovascular risk factors, biostatistics, clinical significance. Where are we?].
Topics: Acute Coronary Syndrome; Atherosclerosis; Biometry; Dyslipidemias; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Metformin; Oxidative Stress; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2007 |
[Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia].
Topics: Analysis of Variance; Dyslipidemias; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Inflammation; Interleukin-6; Metformin; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2007 |
Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension.
Topics: Animals; Carbazoles; Desoxycorticosterone; Dose-Response Relationship, Drug; Fluorobenzenes; Hypertension; In Vitro Techniques; Indoles; Ketanserin; Male; Mesenteric Arteries; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Signal Transduction; Sumatriptan; Thiophenes; Vascular Resistance; Vasoconstriction | 2002 |